恩杂鲁胺在尿路上皮癌中的作用机制见解与未来方向：第10届利奥与安妮·阿尔伯特膀胱癌护理与研究研讨会亮点
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium.
作者信息
Fahey Catherine C, Clark-Garvey Sean, Porten Sima, Kamat Ashish M, Flaig Thomas W, Taylor John A, Kim William Y, Milowsky Matthew I
机构信息
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Department of Urology, University of California, San Francisco, CA 94143, USA.
出版信息
Curr Oncol. 2025 May 14;32(5):278. doi: 10.3390/curroncol32050278.
Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023 annual meeting, the entire treatment landscape for mUC has been upended. At the 2024 Albert Symposium, we reviewed ongoing research investigating predictive biomarkers for EV response and resistance as well as clinical trials exploring the potential role for EV in different clinical disease states including non-muscle invasive and muscle-invasive disease.
恩杂鲁胺（EV）联合帕博利珠单抗（P）为转移性尿路上皮癌（mUC）的治疗带来了新的模式。自EV-302试验结果在2023年欧洲医学肿瘤学会年会上公布以来，mUC的整个治疗格局已被颠覆。在2024年阿尔伯特研讨会上，我们回顾了正在进行的研究，这些研究调查了EV反应和耐药的预测生物标志物，以及探索EV在包括非肌层浸润性和肌层浸润性疾病在内的不同临床疾病状态中的潜在作用的临床试验。
Zotero 插件